110311-30-3

Basic information

• Product Name: SM 5887
• Synonyms: SM 5887;(7S,9S)-9-Acetyl-9-amino-7-(2-deoxy-β-D-erythro-pentopyranosyloxy)-6,11-dihydroxy-5,7,8,9,10,12-hexahydro-5,12-naphthacenedione·hydrochloride;Amrubicin hydrochloride;Calsed;BHMLHEQFWVQAJS-IERVSNJOSA-N
• CAS NO: 110311-30-3
• Molecular Formula: C25H25NO9.ClH
• Molecular Weight: 519.931
• Mol File: 110311-30-3.mol
• Article Data: 0

Chemical Properties

• Melting Point: 145-151°
• Boiling Point: 717.8°C at 760 mmHg
• Flash Point: 387.9°C
• Appearance: /
• Vapor Pressure: 1.26E-21mmHg at 25°C
• CAS DataBase Reference: SM 5887(CAS DataBase Reference)
• NIST Chemistry Reference: SM 5887(110311-30-3)
• EPA Substance Registry System: SM 5887(110311-30-3)

Safety Data

• Hazardous Substances Data: 110311-30-3(Hazardous Substances Data)

Usage

Description

SM 5887, also known as Amrubicin, is a completely synthetic anthracycline derivative used for the treatment of small and small-cell lung cancers. It mediates its growth inhibitory action via topoisomerase II inhibition and is activated in vivo by the formation of its 13-OH metabolite, amrubicinol, via reaction with carbonyl reductase. Amrubicinol is 10-100 fold more cytotoxic than amrubicin and has shown antitumor activity against non-small-cell lung cancers and untreated extensive stage small-cell lung cancers in phase II clinical trials. The drug has a smaller distribution-volume, shorter half-life in mice, and less chronic cardiotoxicity compared to doxorubicin. It is generally well tolerated with major adverse events being anaemia, leucopenia, thrombocytopenia, and neutropenia. The brand name for SM 5887 is Calsed.

Uses

Used in Oncology:
SM 5887 is used as an anticancer agent for the treatment of small and small-cell lung cancers. It is effective against non-small-cell lung cancers with a response rate exceeding 20% and against untreated extensive stage small-cell lung cancers with a response rate of 78.8%.
Used in Pharmaceutical Industry:
SM 5887 is used as a pharmaceutical drug for the development of cancer treatments. Its unique properties, such as a smaller distribution-volume, shorter half-life, and less chronic cardiotoxicity compared to other anthracyclines, make it a promising candidate for cancer therapy.

Originator

Sumitomo (Japan)

InChI:InChI=1/C25H25NO9.ClH/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31;/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3;1H/t14-,15+,16-,17-,25-;/m0./s1